Voyager Therapeutics enters $100M upfront collaboration with Novartis for SMA and HD gene therapy

Voyager Therapeutics, Inc.

Voyager Therapeutics entered into a license and collaboration agreement with Novartis for AAV capsids for SMA and Huntington's disease programs, with $80M upfront payment and $20M stock purchase.
Voyager eligible for up to $200M in milestones for SMA program and $225M for HD program, plus sales milestones and tiered royalties.
Voyager estimates preliminary cash of $230.7M as of Dec 31, 2023; adjusted to $330.7M after anticipated $100M upfront from Novartis.
Voyager plans to submit IND for VY-TAU01 (Alzheimer's) in first half 2024 and for SOD1 ALS gene therapy in mid-2025.
Voyager entered into a stock purchase agreement and investor agreement with Novartis, including standstill and lock-up restrictions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Voyager Therapeutics, Inc. entered into License and Collaboration Agreement with Novartis Pharma AG valued at $80 million (effective 2023-12-28).

Action: entry
Agreement: license
Counterparty: Novartis Pharma AG
Value: $80 million
Effective: 2023-12-28

Exact text from the filing

On December 28, 2023 (the “Effective Date”), Voyager Therapeutics, Inc. (the “Company”) entered into a License and Collaboration Agreement (the “Collaboration Agreement”) with Novartis Pharma AG (“Novartis”)

View on SEC.gov

Browse all material agreements →

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-000084

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.